Cogentix Medical 10-Q 14 Feb 14 2014 Q3 Quarterly report Financial data

Document_And_Entity_Informatio

Document And Entity Information	9 Months Ended
	Dec. 31, 2013	Feb. 10, 2014
Document and Entity Information [Abstract]	'	'
Entity Registrant Name	'VISION SCIENCES INC /DE/	'
Document Type	'10-Q	'
Current Fiscal Year End Date	'--03-31	'
Entity Common Stock, Shares Outstanding	'	47,554,852
Amendment Flag	'false	'
Entity Central Index Key	'0000894237	'
Entity Current Reporting Status	'Yes	'
Entity Voluntary Filers	'No	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Well-known Seasoned Issuer	'No	'
Document Period End Date	31-Dec-13	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Net sales	$4,507	$3,952	$12,127	$11,087
Cost of sales	3,129	2,820	8,474	7,973
Gross profit	1,378	1,132	3,653	3,114
Selling, general, and administrative expenses	2,304	2,311	7,404	8,205
Research and development expenses	552	347	1,399	1,361
Operating loss	-1,478	-1,526	-5,150	-6,452
Interest income	'	1	1	4
Interest expense	-58	-36	-143	-467
Other, net	-18	-6	-16	-47
Debt cost expense	'	'	'	-272
Loss on extinguishment of debt	'	'	'	-1,244
Loss before provision for income taxes	-1,554	-1,567	-5,308	-8,478
Income tax provision	8	10	11	10
Net loss	($1,562)	($1,577)	($5,319)	($8,488)
Net loss per common share - basic and diluted (in Dollars per share)	($0.03)	($0.03)	($0.12)	($0.18)
Weighted average shares used in computing net loss per common share - basic and diluted (in Shares)	46,163	46,051	46,139	45,902

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $)	Dec. 31, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$1,122	$788
Accounts receivable, less allowances of $106 and $113, respectively	3,410	3,624
Inventories, net	5,394	5,158
Prepaid expenses and other current assets	313	276
Total current assets	10,239	9,846
Machinery and equipment	3,456	3,489
Demo equipment	1,268	1,101
Furniture and fixtures	225	225
Leasehold improvements	372	372
Property and equipment, at cost	5,321	5,187
Less—accumulated depreciation and amortization	4,142	3,733
Total property and equipment, net	1,179	1,454
Other assets, net	67	77
Total assets	11,485	11,377
Current liabilities:	'	'
Accounts payable	1,085	1,300
Accrued expenses	897	728
Accrued compensation	648	656
Deferred revenue	183	130
Capital lease obligations	34	75
Total current liabilities	2,847	2,889
Convertible debt—related party, net	21,804	17,000
Deferred revenue, net of current portion	76	62
Capital lease obligations, net of current portion	'	22
Total liabilities	24,727	19,973
Commitments and Contingencies	'	'
Stockholders’ deficit:	'	'
Common stock, $0.01 par value Authorized—75,000 shares; issued and outstanding—47,614 shares and 46,249 shares, respectively	476	463
Additional paid-in capital	101,507	100,819
Treasury stock at cost, 59 shares and 34 shares of common stock, respectively	-78	-50
Accumulated deficit	-115,147	-109,828
Total stockholders’ deficit	-13,242	-8,596
Total liabilities and stockholders’ deficit	$11,485	$11,377

Condensed_Consolidated_Balance1

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) (USD $)	Dec. 31, 2013	Mar. 31, 2013
In Thousands, except Share data, unless otherwise specified
Accounts receivable, allowances (in Dollars)	$106	$113
Preferred Stock Par Value (in Dollars per share)	$0.01	$0.01
Preferred Stock, Authorized Shares	5,000,000	5,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common Stock, Par Value (in Dollars per share)	$0.01	$0.01
Common Stock, Authorized Shares	75,000,000	75,000,000
Common Stock, Shares Issued	47,614,000	46,249,000
Common Stock, Shares Outstanding	47,614,000	46,249,000
Treasury Stock, Shares	59,000	34,000

Condensed_Consolidated_Stateme1

Condensed Consolidated Statement of Stockholders’ Deficit (Unaudited) (USD $)	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
In Thousands
Balance at Mar. 31, 2013	$463	$100,819	($50)	($109,828)	($8,596)
Balance (in Shares) at Mar. 31, 2013	46,249	'	34	'	46,249
Issuance of restricted stock awards	13	-13	'	'	'
Issuance of restricted stock awards (in Shares)	1,365	'	'	'	'
Common stock repurchased	'	'	-28	'	-28
Common stock repurchased (in Shares)	'	'	25	'	'
Beneficial conversion feature	'	202	'	'	202
Stock-based compensation expense	'	499	'	'	499	[1]
Net loss	'	'	'	-5,319	-5,319
Balance at Dec. 31, 2013	$476	$101,507	($78)	($115,147)	($13,242)
Balance (in Shares) at Dec. 31, 2013	47,614	'	59	'	47,614
[1]	Reflects reversal of stock-based compensation expense of $289 thousand for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.

Condensed_Consolidated_Stateme2

Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012
Cash flows from operating activities:	'		'
Net loss	($5,319)		($8,488)
Adjustments to reconcile net loss to net cash used in operating activities:	'		'
Depreciation and amortization	532		603
Stock-based compensation expense	499	[1]	1,209
Provision for (recovery of) bad debt expenses	16		-4
Loss on disposal of fixed assets	5		51
Non-cash interest expense	6		'
Debt cost expense	'		272
Loss on extinguishment of debt	'		1,244
Changes in assets and liabilities:	'		'
Accounts receivable	198		-684
Inventories	-465		-1,062
Prepaid expenses and other current assets	-37		-21
Other assets	10		'
Accounts payable	-215		334
Accrued expenses	169		-325
Accrued compensation	-8		192
Deferred revenue	67		49
Advances from customers	'		-529
Net cash used in operating activities	-4,542		-7,159
Cash flows from investing activities:	'		'
Purchases of property and equipment	-53		-93
Proceeds from disposal of fixed assets	3		5
Net cash used in investing activities	-50		-88
Cash flows from financing activities:	'		'
Proceeds from issuance of convertible debt—related party	5,000		'
Proceeds from promissory note—related party	'		5,000
Net proceeds from sale of common stock	878		878
Proceeds from exercise of stock options	'		99
Common stock repurchased	-28		-36
Payments of capital leases	-46		-73
Net cash provided by financing activities	4,926		5,868
Net increase (decrease) in cash and cash equivalents	334		-1,379
Cash and cash equivalents at beginning of period	788		2,674
Cash and cash equivalents at end of period	1,122		1,295
Cash paid during the period for:	'		'
Interest	11		589
Income taxes	11		17
Non-cash financing activities:	'		'
Beneficial conversion feature	202		'
Net transfers of inventory to fixed assets for use as demonstration equipment	$229		$151
[1]	Reflects reversal of stock-based compensation expense of $289 thousand for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.

Note_1_Summary_of_Significant_

Note 1. Summary of Significant Accounting Policies	9 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Significant Accounting Policies [Text Block]	'
	Note 1.  Summary of Significant Accounting Policies
	Vision-Sciences, Inc. and its subsidiaries (the “Company,” or “our”, “us” or “we”) designs, develops, manufactures, and markets products for endoscopy – the science of using an instrument, known as an endoscope, to provide minimally invasive access to areas not readily visible to the human eye. Our products are sold throughout the world through direct sales representatives in the United States (“U.S.”) and independent distributors for the rest of the world. With respect to our urology products, we are the exclusive supplier to the Endoscopy Division of Stryker Corporation (“Stryker”). Our largest geographic markets are the U.S. and Europe.
	We are incorporated in Delaware, and are the successor to operations begun in 1987. In December 1990, Machida Incorporated (“Machida”) became our wholly-owned subsidiary. We own the trademarks Vision SciencesTM and Slide-OnTM and the registered trademarks EndoSheath®, EndoWipe® and The Vision System®. Not all products referenced in this report are approved or cleared for sale, distribution, or use.
	Basis of Presentation and Preparation
	We have prepared the condensed consolidated financial statements included herein according to generally accepted accounting principles in the United States of America (“U.S. GAAP”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and include, in the opinion of management, all adjustments that we consider necessary for a fair presentation of such information. We have condensed or omitted certain information and footnote disclosures normally included in financial statements pursuant to those rules and regulations. We believe, however, that our disclosures are adequate to make the information presented not misleading.
	The results for the interim periods presented are not necessarily indicative of results to be expected for the full fiscal year. Please read these condensed consolidated financial statements in conjunction with the consolidated financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2013.
	Liquidity and Capital Resources
	We have incurred substantial operating losses since our inception and there can be no assurance that we will ever achieve or sustain a profitable level of operations in the future. We anticipate negative cash flows from operations during the remainder of fiscal 2014, driven by continued investment in a direct sales force for the U.S. market, spending for marketing, spending for research and development, and general business operations. As of December 31, 2013, we had cash and cash equivalents totaling approximately $1.1 million. We expect that our cash at December 31, 2013, together with the $1.5 million of capital available as of December 31, 2013 under a $3.5 million revolving convertible promissory note dated September 25, 2013 (the “2013 Note”) and up to $5.0 million of capital to be made available to us, subject to certain conditions and an expiration date of July 1, 2014, under a letter agreement dated June 21, 2013 with Lewis C. Pell, our Chairman (the “Letter Agreement”) (see Note 5. Convertible Debt – Related Party for additional information), should be sufficient to fund our operations through at least December 31, 2014. However, if our performance expectations fall short (including our failure to generate expected levels of sales) or our expenses exceed expectations, or if the commitments under the 2013 Note or the Letter Agreement become unavailable, we will need to secure additional financing and/or reduce our expenses to continue our operations. Our failure to do so would have a material adverse impact on our prospects and financial condition. There can be no assurance that any contemplated additional financing will be available on terms acceptable to us, if at all. If required, we believe we would be able to reduce our expenses to a sufficient level to continue to operate as a going concern.
	Summary of Significant Accounting Policies
	Our condensed consolidated financial statements are prepared in accordance with U.S. GAAP. These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable, based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. To the extent there are any differences (other than nominal differences) between these estimates, judgments or assumptions and actual results, our financial statements will be affected.
	The accounting policies that reflect our more significant estimates, judgments, and assumptions and that we believe are the most critical to aid in fully understanding and evaluating our reported financial results include the following:
	• Revenue recognition;
	• Stock-based compensation expense;
	• Allowances for doubtful accounts;
	• Inventory obsolescence and realization;
	• Fair value measurements of convertible debt – related party;
	• Obligations under warranties; and
	• Other contingencies.
	The accompanying condensed consolidated financial statements reflect the accounts of the Company. All significant inter-company accounts and transactions have been eliminated in consolidation.
	Fair Value Measurements
	The carrying amounts reflected in our condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued expenses, accrued compensation, and capital lease obligations approximate fair value due to their short-term nature. The fair value of our convertible debt – related party is based on its face value, which is equal to its net carrying value.
	In determining the fair value of the convertible debt – related party, we analyzed its attributes (coupon rate, conversion price, and the percentage of market cap the face value of the debt instrument was prior to the announcement of the debt) as compared to public company convertible debt issuances for an eleven (11) to sixteen (16) month period in the healthcare industry. We determined the convertible debt was not issued at a discount as its fair value was equal to its face (carrying) value.
	Concentration of Credit Risk
	Concentration of credit risk with respect to accounts receivable relates to certain domestic and international customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, when appropriate, we obtain advance payments for our international sales. As a consequence, we believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced any significant credit losses related to any individual customer or group of customers in any particular industry or geographic area.
	The following table summarizes net sales to our most significant customer during the three and nine months ended December 31, 2013, which is our only customer that accounted for more than 10% of total net sales and total accounts receivable, net, during such periods:
		Three Months Ended						Nine Months Ended
		December 31,						December 31,
		2013			2012			2013			2012
	Customer
	Stryker	$	1,202		$	923		$	3,548		$	1,931
	Percentage of total net sales		27	%		23	%		29	%		17	%
	Percentage of total accounts receivable, net		31	%		33	%		31	%		33	%

Note_2_Basic_and_Diluted_Net_L

Note 2. Basic and Diluted Net Loss per Common Share	9 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	Note 2.  Basic and Diluted Net Loss per Common Share
	Basic net loss per share is calculated by dividing the net loss by the weighted average number of common shares outstanding. For all periods presented, the diluted net loss per common share is the same as basic net loss per common share, as the inclusion of other shares of stock issuable pursuant to stock options, warrants, and convertible debt would be anti-dilutive.
	The following table summarizes equity securities that were excluded from the calculation of fully diluted loss per share as of December 31, 2013 and 2012.
		December 31,
		2013		2012
	Convertible debt		18,913,857		12,500,000
	Stock options		4,341,174		5,982,069
	Warrants		1,880,620		1,880,620
	Restricted stock		1,366,652		146,825
	Total anti-dilutive securities		26,502,303		20,509,514

Note_3_Inventories

Note 3. Inventories	9 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Inventory Disclosure [Text Block]	'
	Note 3.  Inventories
	Inventories are stated at the lower of cost or market using the first-in, first-out (“FIFO”) method and consist of the following:
		December 31,		March 31,
		2013		2013
	Raw materials	$	4,342	$	4,352
	Work in process		406		427
	Finished goods		646		379
	Inventories, net	$	5,394	$	5,158
	Raw materials include components purchased from independent suppliers. Most purchased components are available from multiple sources, with the exception of certain key components which are supplied to us by key suppliers, with whom we have long-term supply arrangements, but no long-term supply agreements.

Note_4_Supply_Agreement

Note 4. Supply Agreement	9 Months Ended
	Dec. 31, 2013
Deferred Revenue Disclosure [Abstract]	'
Deferred Revenue Disclosure [Text Block]	'
	Note 4.  Supply Agreements
	We are the exclusive supplier of the following Stryker-branded flexible endoscopes and co-branded EndoSheath technology:
	Market	Product	Term
	Urology	URT-7000 Video Ureteroscope	3-year agreement (December 2012 - December 2015)
		CST-5000 Video Cystoscope	3-year agreement (April 2011 - April 2014)
		CST-4000 Fiber Cystoscope	3-year agreement (April 2011 - April 2014)
		EndoSheath technology (cystoscopy only)	3-year agreement (April 2011 - April 2014)
		Peripherals and accessories (ureteroscopy)	3-year agreement (December 2012 - December 2015)
		Peripherals and accessories (cystoscopy)	3-year agreement (April 2011 - April 2014)
	Until the expiration dates noted, Stryker has the exclusive rights to distribute products we manufacture in North America, South America, Latin America, China, and Japan. Although Stryker was to receive the exclusive rights for the rest of the world in April 2012, we reached an agreement with Stryker to delay this launch indefinitely. With respect to the products for which the exclusive relationship with Stryker expires in April 2014, there can be no assurance that we will be able to successfully negotiate the continuation of such exclusivity with Stryker beyond the expiration date on favorable terms, if at all.
	We also have a development and supply agreement with SpineView, Inc. (“SpineView”) under which we developed and supply a charge-coupled device (CCD) based video surgical endoscope for use with SpineView’s products. In December 2012, SpineView received 510(k) clearance from the U.S. Food and Drug Administration (the “FDA”) to use our system for spine applications. With this clearance and the units supplied from the initial stocking order of 50 SpineView surgical endoscope systems, the balance of which was fulfilled during fiscal 2013, SpineView continues to conduct clinical preference trials for minimally invasive spine surgeries. As a result, we do not anticipate any sales to SpineView during the remainder of fiscal 2014.
	We received advances from Stryker for future orders and from SpineView for the initial stocking order. All of the advances were fully utilized as of September 30, 2012.

Note_5_Convetible_Debt_Related

Note 5. Convetible Debt - Related Party	9 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
	Note 5.  Convertible Debt – Related Party
	Convertible Promissory Notes
	On September 25, 2013 (the “Effective Date”), we entered into the 2013 Note with Mr. Pell, which made $3.5 million of capital available to us. The 2013 Note accrues annual interest, payable annually, at the rate of 1.66%. The 2013 Note must be repaid in full on or before the fifth anniversary of the Effective Date (the “Maturity Date”), but may be prepaid by us at any time without penalty. We will be required to repay all amounts outstanding under the 2013 Note upon an event of default, as defined in the 2013 Note. The outstanding principal amount of the 2013 Note is convertible at any time prior to the Maturity Date, at Mr. Pell’s option, into shares of our common stock at a price of $0.89, the closing bid price of our common stock on the Effective Date. At December 31, 2013, we had outstanding principal borrowings of $2.0 million, gross of the amount recognized as a beneficial conversion feature, under the 2013 Note.
	As we draw upon the 2013 Note, a beneficial conversion feature will be recorded if the market price of our common stock increases after the Effective Date. The following table summarizes the beneficial conversion feature amounts recorded as of December 31, 2013:
	Date	Borrowing		Convertible			Share		Gross
		Amount		Shares			Price		Beneficial
									Conversion
									Feature
	7-Oct-13	$	1,000		1,123,595		$	0.95	$	67
	26-Nov-13		1,000		1,123,595			1.01		135
		$	2,000		2,247,190				$	202
	The beneficial conversion feature amounts were recorded as a convertible debt discount with a corresponding increase to additional paid-in capital. The amounts are being amortized over a five-year period from the borrowing date to the Maturity Date. At December 31, 2013, the unamortized convertible debt discount balance was $196 thousand and is expected to be recognized over a period of approximately 4.7 years.
	On September 19, 2012 (the “Replacement Note Effective Date”), we entered into a $20.0 million revolving convertible promissory note (the “Replacement Note”) with Mr. Pell. The Replacement Note (i) consolidated and restructured the $15.0 million in aggregate borrowings collectively outstanding under an Amended and Restated Loan Agreement, dated September 30, 2011, between us and Mr. Pell (the “Original Agreement”) and a separate promissory note, dated July 25, 2012, between us and Mr. Pell, and (ii) provided for up to $5.0 million in additional borrowings.
	The Replacement Note accrues annual interest, payable annually, at the rate of 0.84%. The Replacement Note must be repaid in full on or before the fifth anniversary of the Replacement Note Effective Date (the “Replacement Note Maturity Date”), but may be prepaid by us at any time without penalty. We will be required to repay all amounts outstanding under the Replacement Note upon an event of default, as defined in the Replacement Note.
	The outstanding principal amount of the Replacement Note is convertible at any time prior to the Replacement Note Maturity Date, at Mr. Pell’s option, into shares of our common stock at a conversion price of $1.20 per share, which was the closing bid price of our common stock on the Replacement Note Effective Date. At December 31, 2013, we had $20.0 million in outstanding principal borrowings under the Replacement Note, which is reflected as convertible debt – related party on our condensed consolidated balance sheet.
	The following table is a summary of our convertible debt-related party at December 31, 2013:
	Convertible Debt—Related Party	Gross		Unamortized			Net
		Principal		Debt			Amount
		Amount		Discount			Outstanding
		Outstanding
	Replacement Note	$	20,000	$	-		$	20,000
	2013 Note		2,000		(196	)		1,804
		$	22,000	$	(196	)	$	21,804
	Pursuant to the Original Agreement, Mr. Pell received warrants to purchase an aggregate of 1,880,620 shares of our common stock at a weighted average exercise price of $1.86 per share. All of the warrants are vested and expire on the later of September 30, 2016 or one year after the termination of the Original Agreement and repayment of all amounts due and payable under the Original Agreement.
	In connection with the issuance of the Replacement Note and the termination of the Original Agreement, we determined that the transaction should be classified as an extinguishment of debt. Accordingly, we wrote-off the remaining deferred debt cost balance of $1.2 million at September 19, 2012.
	We estimated the fair value of all of the stock warrants issued on the date of vesting using a Black-Scholes valuation model that used the weighted average assumptions for the risk-free interest rate, expected life (in years), and expected volatility. We recorded the transaction as a deferred debt cost and amortized to expense over the term of the loan.
	Debt cost expense related to the stock warrants and interest expense related to the availability fee, accrued interest on outstanding borrowings, and amortization of the convertible debt discount for the three and nine months ended December 31, 2013 and 2012 were recorded in our condensed consolidated statement of operations as follows:
		Three Months Ended					Nine Months Ended
		December 31,					December 31,
		2013		2012			2013		2012
	Debt cost expense	$	-	$	-		$	-	$	272
	Interest expense		56		32			137		454
	At December 31, 2013, we had an aggregate amount of $201 thousand in accrued interest under the Replacement Note and the 2013 Note, which is included in accrued expenses on our condensed consolidated balance sheet.
	Letter Agreement
	Pursuant to the Letter Agreement, Mr. Pell has agreed to provide financial assistance to us in the amount of up to $5.0 million, if necessary to support our operations, for a period ending on the earlier of (i) July 1, 2014 or (ii) our raising debt or equity capital in the amount of $5.0 million or more. This financial assistance, if drawn by us, would be in the form of an additional loan, share purchase, or financing transaction, on such terms as we and Mr. Pell may determine. As of December 31, 2013, we had not utilized the financial assistance agreement.

Note_6_Common_Stock

Note 6. Common Stock	9 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Stockholders' Equity Note Disclosure [Text Block]	'
	Note 6.  Common Stock
	On April 27, 2012, we entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“LPC”), pursuant to which we have the right to sell to LPC up to $15.0 million in shares of our common stock from time-to-time over a period of up to three years, subject to certain limitations and conditions set forth in the Purchase Agreement. This total maximum amount of $15.0 million would increase to $21.0 million if the aggregate market value of shares of our common stock held by non-affiliates reached at least $75.0 million during the three-year term of the Purchase Agreement. The Purchase Agreement contains customary representations, warranties and agreements between us and LPC, limitations (market price of our common stock and LPC’s ownership limit) and conditions to completing future sale transactions, indemnification rights and other obligations of the parties. In connection with the initial purchase under the Purchase Agreement, and any future sales under the Purchase Agreement, Mr. Pell waived the repayment requirement under the Original Agreement. On July 26, 2012, we amended the Purchase Agreement with LPC to, among other things, create a threshold price of $3.00 for the sale of our common stock to LPC, as calculated pursuant to the formula provided in the Purchase Agreement.
	As consideration for LPC entering into the Purchase Agreement and for its initial purchase of $1.0 million of our common stock in April 2012, we issued to LPC 175,333 shares of our common stock. As consideration for LPC’s remaining future purchases under the Purchase Agreement, we also will issue to LPC, on a pro rata basis in connection with each purchase of shares by LPC, up to a total of approximately 215,000 additional shares of our common stock. We did not receive any cash proceeds from the issuance of 175,333 shares and will not receive any proceeds upon the issuance of any of the remaining 215,000 shares.
	The following table summarizes the common stock issued and cash received in connection with the Purchase Agreement:
	Month	Description	Number of		Share		Gross
			Shares of		Price		Proceeds
			Common Stock
			Issued
	Apr-12	Initial purchase shares		599,880	$	1.667	$	1,000
	Apr-12	Initial commitment shares		160,000		-		-
	Apr-12	Initial additional commitment shares (1)		15,333		-		-
				775,213			$	1,000
	(1) Calculated as follows: ($1.0 million stock purchase divided by $15.0 million total maximum amount) multiplied by 230,000 additional commitment shares.
	In connection with the Purchase Agreement, we incurred $122 thousand of costs associated with investment banking fees, legal fees, and expense reimbursement to LPC. Our net proceeds from the sale of the initial purchase shares were $878 thousand.

Note_7_StockBased_Awards

Note 7. Stock-Based Awards	9 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	Note 7.  Stock-Based Awards
	We maintain the following stockholder-approved equity incentive plans:
		●	The 2000 Stock Incentive Plan (the “2000 Plan”) authorized the issuance of up to 4,500,000 shares of common stock covering several different types of awards, including stock options, restricted shares, stock appreciation rights, and performance shares.
		●	The 2007 Stock Incentive Plan (the “2007 Plan”) authorized the issuance of up to 5,000,000 shares of common stock covering several different types of awards, including stock options, restricted shares, stock appreciation rights, and other stock-based awards. On July 26, 2012, our stockholders approved an amendment to the 2007 Plan further increasing the number of authorized shares issuable under the plan to 7,000,000 shares of common stock.
		●	The 2003 Director Option Plan (the “2003 Plan”) authorized the issuance of up to 450,000 shares of common stock covering the annual automatic grant, unless waived, of 10,000 stock options per outside director per year. The 2003 Plan also provides for granting newly elected or appointed outside directors a one-time grant of 10,000 stock options.
	The stock option plans provide that options may be granted at an exercise price of 100% of fair market value of our common stock on the date of grant, may be exercised in full or in installments, at the discretion of our Board of Directors (the “Board”) or its Compensation Committee (the “Compensation Committee”), and must be exercised within ten years from date of grant. We recognize stock-based compensation expense on a straight-line basis over the requisite service period based on fair values, generally four years. We use historical data to estimate expected employee behaviors related to option exercises and forfeitures and included these expected forfeitures as a part of the estimate of stock-based compensation expense as of the grant date.
	Stock Options
	The following table summarizes stock options activity for the nine months ended December 31, 2013:
			Number			Exercise				Weighted			Weighted
			of Shares			Price Range				Average			Average
										Exercise Price			Remaining
													Contractual Life
	Outstanding at March 31, 2013			5,780,608		$0.79	–	$4.88		$	2.09			6.6
	Granted			966,000		$0.90	–	$1.09			1
	Exercised			-			-				-
	Canceled (1)			(2,405,434	)	$0.95	–	$3.62			2.21
	Outstanding at December 31, 2013			4,341,174		$0.85	–	$4.88		$	1.8			6.1
	Exercisable at December 31, 2013			3,430,403		$0.85	–	$4.88		$	1.93			5.3
	Vested and expected to vest at December 31, 2013			4,259,506		$0.85	–	$4.88		$	1.81			6
	(1) Includes cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari (1,125,000 stock options), and our former VP, Corporate Development and Chief Financial Officer, Katherine L. Wolf (612,458 stock options).
	The weighted average fair value of options granted during the three months ended December 31, 2013 and 2012 was $0.56 and $0.79 per share, respectively. The weighted average fair value of options granted during the nine months ended December 31, 2013 and 2012 was $0.65 and $0.92 per share, respectively.
	The total intrinsic value (the excess of the market price over the exercise price) was approximately $37 thousand for stock options outstanding, $29 thousand for stock options exercisable, and $36 thousand for stock options vested and expected to vest as of December 31, 2013. The total intrinsic value for stock options exercised during the three and nine months ended December 31, 2012 was approximately $2 thousand and $25 thousand, respectively. There were no stock options exercised during the three and nine months ended December 31, 2013.
	We do not expect to realize any tax benefits from future disqualifying dispositions, if any, because we currently have a full valuation allowance against our deferred tax assets.
	Restricted Stock
	The following table summarizes restricted stock activity for the nine months ended December 31, 2013:
			Number			Weighted
			of Shares			Average
						Grant Price
	Nonvested at March 31, 2013			122,044		$	2.37
	Granted			1,365,000			1
	Vested			(120,392	)		1.74
	Forfeited			-			-
	Nonvested at December 31, 2013			1,366,652		$	1.06
	We grant restricted stock awards (“RSA’s”) to our executive officers and management employees (collectively “management”) and members of our Board from time-to-time. There is no direct costs to the recipients of the RSA’s, except for any applicable taxes upon lapsing of the restrictions. In fiscal 2011, the Compensation Committee adopted a performance incentive plan (“PIP”) that provides for the payment of bonuses to management based on the attainment of specified Company performance and individual objectives. Any payments that may be due under the PIP will be paid in shares of restricted stock awarded under our 2007 Plan. The nonvested balance of 207,902 shares represent RSAs awarded to management under the fiscal 2012 PIP and to Board members for the annual grant at our fiscal 2013 annual stockholders meeting. The Compensation Committee did not approve a PIP for fiscal 2013.
	On November 26, 2013 (the “Appointment Date”), at the time of his appointment as President and Chief Executive Officer, Howard Zauberman was granted 1,200,000 shares of restricted stock, which is included in the number granted during the three and nine months ended December 31, 2013. The restrictions on Mr. Zauberman’s restricted stock will lapse over four years (subject to further vesting as described below) commencing on the Appointment Date as follows: up to 300,000 shares become unrestricted each year, upon Mr. Zauberman’s achievement of predetermined Company milestones and individual performance objectives (the “Milestones”) based on a plan developed to be by Mr. Zauberman and approved by the Board within 90 days of the Appointment Date (the “Plan”). If a Milestone is not achieved, the shares of restricted stock tied to that Milestone are cancelled.
	Those restricted shares for which restrictions have been removed as a result of Mr. Zauberman’s achieving Milestones as described above will then vest in four equal annual installments (each, a “Full Vesting Date”). If prior to a Full Vesting Date, Mr. Zauberman’s service to us is terminated for cause (as defined in his employment agreement), or if Mr. Zauberman voluntarily terminates his service with us, then the restricted shares that have not yet vested will be forfeited (even if a Milestone has previously been achieved with respect to such shares). If Mr. Zauberman is terminated without cause (as defined in his employment agreement), then all restricted shares for which restrictions have been removed will vest, but any restricted shares for which a Milestone has not yet been met shall be cancelled.
	Stock-Based Compensation Expense
	We account for stock-based awards issued to employees in accordance with the provisions of ASC 718 (Topic 718, Compensation – Stock Compensation). We recognize stock-based compensation expense on a straight-line uniform basis over the service period of the award, which is generally four years for employees. Stock-based awards issued to consultants are accounted for in accordance with the provisions of ASC 718 and ASC 505-50 (Subtopic 50 “Equity-Based Payments to Non-Employees” of Topic 505, Equity). Options granted to consultants are periodically revalued as the options vest, and are recognized as an expense over the related period of service or the vesting period, whichever is longer. Under the provisions of ASC 718, members of the Board are considered employees for calculation of stock-based compensation expense.
	We estimated the fair value of the stock options granted on the date of grant using a Black-Scholes valuation model that used the weighted average assumptions noted in the following table. The risk-free interest rate assumption we use is based upon United States Treasury interest rates appropriate for the expected life of the awards. The expected life (estimated period of time that we expect employees, consultants and directors to hold their stock options) was estimated based on historical rates for two group classifications, (i) employees and consultants and (ii) outside directors. Expected volatility was based on historical volatility of our stock price for a period equal to the stock option’s expected life and calculated on a daily basis. The expected dividend rate is zero since we do not currently pay cash dividends on our common stock and do not anticipate doing so in the foreseeable future.
			Three Months Ended						Nine Months Ended
			December 31,						December 31,
			2013			2012			2013			2012
	Risk-free interest rate		1.38	%		0.91	%		1.21	%		1.02	%
	Expected life (in years)		5.1			6.3			5.4			6.4
	Expected volatility		73	%		81	%		78	%		84	%
	Expected dividend yield		--			--			--			--
	We determine stock-based compensation expense for performance based restricted stock based upon the fair value of our common stock at the date of grant and recognize expense based upon the most probable outcome as to whether the performance targets will be achieved and the stock-based compensation being earned.
	Stock-based compensation expense for the three and nine months ended December 31, 2013 and 2012 was recorded in our condensed consolidated statement of operations as follows:
			Three Months Ended						Nine Months Ended
			December 31,						December 31,
			2013			2012			2013			2012
	Cost of sales		$	15		$	6		$	57		$	75
	Selling, general, and administrative expenses (1)			150			185			415			1,092
	Research and development expenses			6			6			27			42
	Total stock-based compensation expense		$	171		$	197		$	499		$	1,209
	(1) Reflects reversal of stock-based compensation expense of $289 thousand in the nine months ended December 31, 2013 for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.
	At December 31, 2013, unrecognized stock-based compensation expense related to stock options was approximately $0.6 million and is expected to be recognized over a weighted average period of approximately 2.6 years. At December 31, 2013, unrecognized stock-based compensation expense related to nonvested (restricted stock) awards was approximately $1.3 million, which is expected to be recognized over a weighted average period of approximately 6.6 years.

Note_8_Treasury_Stock

Note 8. Treasury Stock	9 Months Ended
	Dec. 31, 2013
Disclosure Text Block Supplement [Abstract]	'
Treasury Stock [Text Block]	'
	Note 8.  Treasury Stock
	The following table summarizes treasury stock activity for the three and nine months ended December 31, 2013 and 2012:
	Three Months Ended	Number		Cost		Weighted
		of Shares				Average
		Repurchased				Purchase Price
	31-Dec-13		-		-		-
	31-Dec-12		9,912	$	12	$	1.26
	Nine Months Ended
	31-Dec-13		25,525	$	28	$	1.11
	31-Dec-12		27,329	$	36	$	1.32
	The shares were purchased from management to cover income tax withholdings upon the lapse of restrictions on their restricted stock awards. Although not required to under our equity incentive plans, we anticipate repurchasing shares in a similar arrangement in the future.

Note_9_Segment_Information

Note 9. Segment Information	9 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Segment Reporting Disclosure [Text Block]	'
	Note 9.  Segment Information
	We have two reportable segments, medical and industrial. Each of these operating segments has unique characteristics. Management evaluates the revenue and profitability performance of each of our product lines to make operating and strategic decisions. We have no intersegment revenue.
	Our medical segment designs, develops, manufactures, and markets our advanced line of endoscopy-based products, including our state-of-the-art flexible endoscopes, and our EndoSheath technology (referred to as a sheath or EndoSheath disposable) for a variety of specialties and markets.
	Our industrial segment, through our wholly-owned subsidiary Machida, designs, manufactures, and sells borescopes to a variety of users, primarily in the aircraft engine manufacturing and aircraft engine maintenance industries. A borescope is an instrument that uses optical fibers for the visual inspection of narrow cavities. Our borescopes are used to inspect aircraft engines, casting parts and ground turbines, among other items.
	The following table presents key financial highlights, by reportable segments:
	Three Months Ended	Medical			Industrial			Adjustments *			Consolidated
	31-Dec-13
	Net sales	$	3,586		$	921		$	-		$	4,507
	Gross profit		996			382			-			1,378
	Operating (loss) income		(1,676	)		198			-			(1,478	)
	Interest expense, net		(58	)		-			-			(58	)
	Depreciation and amortization		168			2			-			170
	Stock-based compensation expense		160			11			-			171
	Total assets		11,736			1,591			(1,842	)		11,485
	Expenditures for fixed assets		7			-			-			7
	31-Dec-12
	Net sales	$	2,970		$	982		$	-		$	3,952
	Gross profit		728			404			-			1,132
	Operating (loss) income		(1,750	)		224			-			(1,526	)
	Interest expense, net		(35	)		-			-			(35	)
	Depreciation and amortization		192			5			-			197
	Stock-based compensation expense		182			15			-			197
	Total assets		10,885			1,783			(1,759	)		10,909
	Expenditures for fixed assets		38			-			-			38
	Nine Months Ended
	31-Dec-13
	Net sales	$	10,013		$	2,114		$	-		$	12,127
	Gross profit		2,770			883			-			3,653
	Operating (loss) income		(5,408	)		258			-			(5,150	)
	Interest expense, net		(142	)		-			-			(142	)
	Depreciation and amortization		523			9			-			532
	Stock-based compensation expense (1)		469			30			-			499
	Expenditures for fixed assets		53			-			-			53
	31-Dec-12
	Net sales	$	8,190		$	2,897		$	-		$	11,087
	Gross profit		2,068			1,046			-			3,114
	Operating (loss) income		(6,783	)		331			-			(6,452	)
	Interest expense, net		(463	)		-			-			(463	)
	Depreciation and amortization		585			18			-			603
	Stock-based compensation expense		1,142			67			-			1,209
	Expenditures for fixed assets		93			-			-			93
		December 31,
	* Adjustments	2013			2012
	Intercompany eliminations	$	(1,156	)	$	(1,073	)
	Investment in subsidiaries		(686	)		(686	)
	Total adjustments	$	(1,842	)	$	(1,759	)
	(1) Reflects reversal of stock-based compensation expense of $289 thousand for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.
	The following table presents the reconciliation to loss before provision for income taxes for the three and nine months ended December 31, 2013 and 2012:
		Three Months Ended						Nine Months Ended
		December 31,						December 31,
	Reconciliation to loss before provision for income taxes:	2013			2012			2013			2012
	Operating loss	$	(1,478	)	$	(1,526	)	$	(5,150	)	$	(6,452	)
	Interest expense, net		(58	)		(35	)		(142	)		(463	)
	Other, net		(18	)		(6	)		(16	)		(47	)
	Debt cost expense		-			-			-			(272	)
	Loss on extinguishment of debt		-			-			-			(1,244	)
	Loss before provision for income taxes	$	(1,554	)	$	(1,567	)	$	(5,308	)	$	(8,478	)

Accounting_Policies_by_Policy_

Accounting Policies, by Policy (Policies)	9 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Basis of Accounting, Policy [Policy Text Block]	'
	Summary of Significant Accounting Policies
	Vision-Sciences, Inc. and its subsidiaries (the “Company,” or “our”, “us” or “we”) designs, develops, manufactures, and markets products for endoscopy – the science of using an instrument, known as an endoscope, to provide minimally invasive access to areas not readily visible to the human eye. Our products are sold throughout the world through direct sales representatives in the United States (“U.S.”) and independent distributors for the rest of the world. With respect to our urology products, we are the exclusive supplier to the Endoscopy Division of Stryker Corporation (“Stryker”). Our largest geographic markets are the U.S. and Europe.
	We are incorporated in Delaware, and are the successor to operations begun in 1987. In December 1990, Machida Incorporated (“Machida”) became our wholly-owned subsidiary. We own the trademarks Vision SciencesTM and Slide-OnTM and the registered trademarks EndoSheath®, EndoWipe® and The Vision System®. Not all products referenced in this report are approved or cleared for sale, distribution, or use.
	Basis of Presentation and Preparation
	We have prepared the condensed consolidated financial statements included herein according to generally accepted accounting principles in the United States of America (“U.S. GAAP”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and include, in the opinion of management, all adjustments that we consider necessary for a fair presentation of such information. We have condensed or omitted certain information and footnote disclosures normally included in financial statements pursuant to those rules and regulations. We believe, however, that our disclosures are adequate to make the information presented not misleading.
	The results for the interim periods presented are not necessarily indicative of results to be expected for the full fiscal year. Please read these condensed consolidated financial statements in conjunction with the consolidated financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2013.
	Liquidity and Capital Resources
	We have incurred substantial operating losses since our inception and there can be no assurance that we will ever achieve or sustain a profitable level of operations in the future. We anticipate negative cash flows from operations during the remainder of fiscal 2014, driven by continued investment in a direct sales force for the U.S. market, spending for marketing, spending for research and development, and general business operations. As of December 31, 2013, we had cash and cash equivalents totaling approximately $1.1 million. We expect that our cash at December 31, 2013, together with the $1.5 million of capital available as of December 31, 2013 under a $3.5 million revolving convertible promissory note dated September 25, 2013 (the “2013 Note”) and up to $5.0 million of capital to be made available to us, subject to certain conditions and an expiration date of July 1, 2014, under a letter agreement dated June 21, 2013 with Lewis C. Pell, our Chairman (the “Letter Agreement”) (see Note 5. Convertible Debt – Related Party for additional information), should be sufficient to fund our operations through at least December 31, 2014. However, if our performance expectations fall short (including our failure to generate expected levels of sales) or our expenses exceed expectations, or if the commitments under the 2013 Note or the Letter Agreement become unavailable, we will need to secure additional financing and/or reduce our expenses to continue our operations. Our failure to do so would have a material adverse impact on our prospects and financial condition. There can be no assurance that any contemplated additional financing will be available on terms acceptable to us, if at all. If required, we believe we would be able to reduce our expenses to a sufficient level to continue to operate as a going concern.
	Summary of Significant Accounting Policies
	Our condensed consolidated financial statements are prepared in accordance with U.S. GAAP. These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable, based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the financial statements as well as the reported amounts of revenues and expenses during the periods presented. To the extent there are any differences (other than nominal differences) between these estimates, judgments or assumptions and actual results, our financial statements will be affected.
	The accounting policies that reflect our more significant estimates, judgments, and assumptions and that we believe are the most critical to aid in fully understanding and evaluating our reported financial results include the following:
	• Revenue recognition;
	• Stock-based compensation expense;
	• Allowances for doubtful accounts;
	• Inventory obsolescence and realization;
	• Fair value measurements of convertible debt – related party;
	• Obligations under warranties; and
	• Other contingencies.
	The accompanying condensed consolidated financial statements reflect the accounts of the Company. All significant inter-company accounts and transactions have been eliminated in consolidation.
Business Description and Basis of Presentation [Text Block]	'
	Basis of Presentation and Preparation
	We have prepared the condensed consolidated financial statements included herein according to generally accepted accounting principles in the United States of America (“U.S. GAAP”), without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and include, in the opinion of management, all adjustments that we consider necessary for a fair presentation of such information. We have condensed or omitted certain information and footnote disclosures normally included in financial statements pursuant to those rules and regulations. We believe, however, that our disclosures are adequate to make the information presented not misleading.
	The results for the interim periods presented are not necessarily indicative of results to be expected for the full fiscal year. Please read these condensed consolidated financial statements in conjunction with the consolidated financial statements and the related notes included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2013.
Liquidity Disclosure [Policy Text Block]	'
	Liquidity and Capital Resources
	We have incurred substantial operating losses since our inception and there can be no assurance that we will ever achieve or sustain a profitable level of operations in the future. We anticipate negative cash flows from operations during the remainder of fiscal 2014, driven by continued investment in a direct sales force for the U.S. market, spending for marketing, spending for research and development, and general business operations. As of December 31, 2013, we had cash and cash equivalents totaling approximately $1.1 million. We expect that our cash at December 31, 2013, together with the $1.5 million of capital available as of December 31, 2013 under a $3.5 million revolving convertible promissory note dated September 25, 2013 (the “2013 Note”) and up to $5.0 million of capital to be made available to us, subject to certain conditions and an expiration date of July 1, 2014, under a letter agreement dated June 21, 2013 with Lewis C. Pell, our Chairman (the “Letter Agreement”) (see Note 5. Convertible Debt – Related Party for additional information), should be sufficient to fund our operations through at least December 31, 2014. However, if our performance expectations fall short (including our failure to generate expected levels of sales) or our expenses exceed expectations, or if the commitments under the 2013 Note or the Letter Agreement become unavailable, we will need to secure additional financing and/or reduce our expenses to continue our operations. Our failure to do so would have a material adverse impact on our prospects and financial condition. There can be no assurance that any contemplated additional financing will be available on terms acceptable to us, if at all. If required, we believe we would be able to reduce our expenses to a sufficient level to continue to operate as a going concern.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value Measurements
	The carrying amounts reflected in our condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, other current assets, accounts payable, accrued expenses, accrued compensation, and capital lease obligations approximate fair value due to their short-term nature. The fair value of our convertible debt – related party is based on its face value, which is equal to its net carrying value.
	In determining the fair value of the convertible debt – related party, we analyzed its attributes (coupon rate, conversion price, and the percentage of market cap the face value of the debt instrument was prior to the announcement of the debt) as compared to public company convertible debt issuances for an eleven (11) to sixteen (16) month period in the healthcare industry. We determined the convertible debt was not issued at a discount as its fair value was equal to its face (carrying) value.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentration of Credit Risk
	Concentration of credit risk with respect to accounts receivable relates to certain domestic and international customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, when appropriate, we obtain advance payments for our international sales. As a consequence, we believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced any significant credit losses related to any individual customer or group of customers in any particular industry or geographic area.
	The following table summarizes net sales to our most significant customer during the three and nine months ended December 31, 2013, which is our only customer that accounted for more than 10% of total net sales and total accounts receivable, net, during such periods:

Note_1_Summary_of_Significant_1

Note 1. Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]	'
		Three Months Ended						Nine Months Ended
		December 31,						December 31,
		2013			2012			2013			2012
	Customer
	Stryker	$	1,202		$	923		$	3,548		$	1,931
	Percentage of total net sales		27	%		23	%		29	%		17	%
	Percentage of total accounts receivable, net		31	%		33	%		31	%		33	%

Note_2_Basic_and_Diluted_Net_L1

Note 2. Basic and Diluted Net Loss per Common Share (Tables)	9 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	'
		December 31,
		2013		2012
	Convertible debt		18,913,857		12,500,000
	Stock options		4,341,174		5,982,069
	Warrants		1,880,620		1,880,620
	Restricted stock		1,366,652		146,825
	Total anti-dilutive securities		26,502,303		20,509,514

Note_3_Inventories_Tables

Note 3. Inventories (Tables)	9 Months Ended
	Dec. 31, 2013
Inventory Disclosure [Abstract]	'
Schedule of Inventory, Current [Table Text Block]	'
		December 31,		March 31,
		2013		2013
	Raw materials	$	4,342	$	4,352
	Work in process		406		427
	Finished goods		646		379
	Inventories, net	$	5,394	$	5,158

Note_5_Convetible_Debt_Related1

Note 5. Convetible Debt - Related Party (Tables)	9 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Convertible Debt [Table Text Block]	'
	Date	Borrowing		Convertible			Share		Gross
		Amount		Shares			Price		Beneficial
									Conversion
									Feature
	7-Oct-13	$	1,000		1,123,595		$	0.95	$	67
	26-Nov-13		1,000		1,123,595			1.01		135
		$	2,000		2,247,190				$	202
Schedule of Related Party Transactions [Table Text Block]	'
	Convertible Debt—Related Party	Gross		Unamortized			Net
		Principal		Debt			Amount
		Amount		Discount			Outstanding
		Outstanding
	Replacement Note	$	20,000	$	-		$	20,000
	2013 Note		2,000		(196	)		1,804
		$	22,000	$	(196	)	$	21,804
Schedule of Other Nonoperating Income (Expense) [Table Text Block]	'
		Three Months Ended					Nine Months Ended
		December 31,					December 31,
		2013		2012			2013		2012
	Debt cost expense	$	-	$	-		$	-	$	272
	Interest expense		56		32			137		454

Note_6_Common_Stock_Tables

Note 6. Common Stock (Tables)	9 Months Ended
	Dec. 31, 2013
Stockholders' Equity Note [Abstract]	'
Common Stock Issued and Cash Received in Purchase Agreement	'
	Month	Description	Number of		Share		Gross
			Shares of		Price		Proceeds
			Common Stock
			Issued
	Apr-12	Initial purchase shares		599,880	$	1.667	$	1,000
	Apr-12	Initial commitment shares		160,000		-		-
	Apr-12	Initial additional commitment shares (1)		15,333		-		-
				775,213			$	1,000

Note_7_StockBased_Awards_Table

Note 7. Stock-Based Awards (Tables)	9 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
		Number			Exercise				Weighted			Weighted
		of Shares			Price Range				Average			Average
									Exercise Price			Remaining
												Contractual Life
	Outstanding at March 31, 2013		5,780,608		$0.79	–	$4.88		$	2.09			6.6
	Granted		966,000		$0.90	–	$1.09			1
	Exercised		-			-				-
	Canceled (1)		(2,405,434	)	$0.95	–	$3.62			2.21
	Outstanding at December 31, 2013		4,341,174		$0.85	–	$4.88		$	1.8			6.1
	Exercisable at December 31, 2013		3,430,403		$0.85	–	$4.88		$	1.93			5.3
	Vested and expected to vest at December 31, 2013		4,259,506		$0.85	–	$4.88		$	1.81			6
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	'
		Number			Weighted
		of Shares			Average
					Grant Price
	Nonvested at March 31, 2013		122,044		$	2.37
	Granted		1,365,000			1
	Vested		(120,392	)		1.74
	Forfeited		-			-
	Nonvested at December 31, 2013		1,366,652		$	1.06
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
		Three Months Ended						Nine Months Ended
		December 31,						December 31,
		2013			2012			2013			2012
	Risk-free interest rate	1.38	%		0.91	%		1.21	%		1.02	%
	Expected life (in years)	5.1			6.3			5.4			6.4
	Expected volatility	73	%		81	%		78	%		84	%
	Expected dividend yield	--			--			--			--
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
		Three Months Ended						Nine Months Ended
		December 31,						December 31,
		2013			2012			2013			2012
	Cost of sales	$	15		$	6		$	57		$	75
	Selling, general, and administrative expenses (1)		150			185			415			1,092
	Research and development expenses		6			6			27			42
	Total stock-based compensation expense	$	171		$	197		$	499		$	1,209

Note_8_Treasury_Stock_Tables

Note 8. Treasury Stock (Tables)	9 Months Ended
	Dec. 31, 2013
Disclosure Text Block Supplement [Abstract]	'
Class of Treasury Stock [Table Text Block]	'
	Three Months Ended	Number		Cost		Weighted
		of Shares				Average
		Repurchased				Purchase Price
	31-Dec-13		-		-		-
	31-Dec-12		9,912	$	12	$	1.26
	Nine Months Ended
	31-Dec-13		25,525	$	28	$	1.11
	31-Dec-12		27,329	$	36	$	1.32

Note_9_Segment_Information_Tab

Note 9. Segment Information (Tables)	9 Months Ended
	Dec. 31, 2013
Segment Reporting [Abstract]	'
Schedule of Segment Reporting Information, by Segment [Table Text Block]	'
	Three Months Ended	Medical			Industrial			Adjustments *			Consolidated
	31-Dec-13
	Net sales	$	3,586		$	921		$	-		$	4,507
	Gross profit		996			382			-			1,378
	Operating (loss) income		(1,676	)		198			-			(1,478	)
	Interest expense, net		(58	)		-			-			(58	)
	Depreciation and amortization		168			2			-			170
	Stock-based compensation expense		160			11			-			171
	Total assets		11,736			1,591			(1,842	)		11,485
	Expenditures for fixed assets		7			-			-			7
	31-Dec-12
	Net sales	$	2,970		$	982		$	-		$	3,952
	Gross profit		728			404			-			1,132
	Operating (loss) income		(1,750	)		224			-			(1,526	)
	Interest expense, net		(35	)		-			-			(35	)
	Depreciation and amortization		192			5			-			197
	Stock-based compensation expense		182			15			-			197
	Total assets		10,885			1,783			(1,759	)		10,909
	Expenditures for fixed assets		38			-			-			38
	Nine Months Ended
	31-Dec-13
	Net sales	$	10,013		$	2,114		$	-		$	12,127
	Gross profit		2,770			883			-			3,653
	Operating (loss) income		(5,408	)		258			-			(5,150	)
	Interest expense, net		(142	)		-			-			(142	)
	Depreciation and amortization		523			9			-			532
	Stock-based compensation expense (1)		469			30			-			499
	Expenditures for fixed assets		53			-			-			53
	31-Dec-12
	Net sales	$	8,190		$	2,897		$	-		$	11,087
	Gross profit		2,068			1,046			-			3,114
	Operating (loss) income		(6,783	)		331			-			(6,452	)
	Interest expense, net		(463	)		-			-			(463	)
	Depreciation and amortization		585			18			-			603
	Stock-based compensation expense		1,142			67			-			1,209
	Expenditures for fixed assets		93			-			-			93
Segment Reporting, Measurement Differences Between Segment and Consolidated Profit (Loss)	'
		December 31,
	* Adjustments	2013			2012
	Intercompany eliminations	$	(1,156	)	$	(1,073	)
	Investment in subsidiaries		(686	)		(686	)
	Total adjustments	$	(1,842	)	$	(1,759	)
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	'
		Three Months Ended						Nine Months Ended
		December 31,						December 31,
	Reconciliation to loss before provision for income taxes:	2013			2012			2013			2012
	Operating loss	$	(1,478	)	$	(1,526	)	$	(5,150	)	$	(6,452	)
	Interest expense, net		(58	)		(35	)		(142	)		(463	)
	Other, net		(18	)		(6	)		(16	)		(47	)
	Debt cost expense		-			-			-			(272	)
	Loss on extinguishment of debt		-			-			-			(1,244	)
	Loss before provision for income taxes	$	(1,554	)	$	(1,567	)	$	(5,308	)	$	(8,478	)

Note_1_Summary_of_Significant_2

Note 1. Summary of Significant Accounting Policies (Details) (USD $)	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2012	Mar. 31, 2012
Note 1. Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Cash and Cash Equivalents, at Carrying Value (in Dollars)	$1,122,000	$788,000	$1,295,000	$2,674,000
Chairman, Lewis C. Pell [Member]	'	'	'	'
Note 1. Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Long Term Debt Maximum Amount Lender Agreed To Provide Financial Assistance (in Dollars)	5,000,000	'	'	'
The 2013 Note [Member] | Revolving Convertible Promissory Note [Member]	'	'	'	'
Note 1. Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Convertible Notes Payable (in Dollars)	3,500,000	'	'	'
Stryker [Member] | Sales Revenue, Goods, Net [Member]	'	'	'	'
Note 1. Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Percentage of Total Segment Net Sales and Total Accounts Receivable, Net	10.00%	'	'	'
Convertible Debt [Member]	'	'	'	'
Note 1. Summary of Significant Accounting Policies (Details) [Line Items]	'	'	'	'
Line of Credit Facility, Maximum Borrowing Capacity (in Dollars)	$1,500,000	'	'	'

Note_1_Summary_of_Significant_3

Note 1. Summary of Significant Accounting Policies (Details) - Significant Customers (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Customer	'	'	'	'
Stryker (in Dollars)	$4,507	$3,952	$12,127	$11,087
Stryker [Member] | Medical [Member]	'	'	'	'
Customer	'	'	'	'
Stryker (in Dollars)	1,202	923	3,548	1,931
Percentage of total net sales	27.00%	23.00%	29.00%	17.00%
Percentage of total accounts receivable, net	31.00%	33.00%	31.00%	33.00%
Medical [Member]	'	'	'	'
Customer	'	'	'	'
Stryker (in Dollars)	$3,586	$2,970	$10,013	$8,190

Note_2_Basic_and_Diluted_Net_L2

Note 2. Basic and Diluted Net Loss per Common Share (Details) - Equity Securities Excluded From The Calculation of Fully Diluted Loss Per Share	9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-Dilutive Securities	26,502,303	20,509,514
Convertible Debt Securities [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-Dilutive Securities	18,913,857	12,500,000
Equity Option [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-Dilutive Securities	4,341,174	5,982,069
Warrant [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-Dilutive Securities	1,880,620	1,880,620
Restricted Stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-Dilutive Securities	1,366,652	146,825

Note_3_Inventories_Details_Inv

Note 3. Inventories (Details) - Inventories (USD $)	Dec. 31, 2013	Mar. 31, 2013
In Thousands, unless otherwise specified
Inventories [Abstract]	'	'
Raw materials	$4,342	$4,352
Work in process	406	427
Finished goods	646	379
Inventories, net	$5,394	$5,158

Note_5_Convetible_Debt_Related2

Note 5. Convetible Debt - Related Party (Details) (USD $)

Dec. 31, 2013

Nov. 26, 2013

Oct. 07, 2013

Mar. 31, 2013

Dec. 31, 2013

Sep. 25, 2013

Dec. 31, 2013

Sep. 30, 2011

Dec. 31, 2013

Sep. 19, 2012

Jul. 25, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

The 2013 Note [Member]

The 2013 Note [Member]

The 2013 Note [Member]

Replacement Note [Member]

Replacement Note [Member]

Replacement Note [Member]

Replacement Note [Member]

The Original Agreement [Member]

The Original Agreement [Member]

The Letter Agreement [Member]

Convertible Debt [Member]

Convertible Debt [Member]

Chairman, Lewis C. Pell [Member]

Chairman, Lewis C. Pell [Member]

Note 5. Convetible Debt - Related Party (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes Payable, Related Parties

'

'

'

'

'

$3,500,000

'

'

'

'

'

'

'

'

'

Related Party Transaction, Rate

'

'

'

'

'

1.66%

'

'

0.84%

'

'

'

'

'

'

Debt Instrument, Convertible, Conversion Price (in Dollars per share)

'

$1.01

$0.95

'

'

$0.89

'

'

$1.20

'

'

'

'

'

'

Convertible Debt

2,000,000

1,000,000

1,000,000

'

'

'

2,000,000

'

'

'

'

'

'

'

'

Debt Instrument, Unamortized Discount

'

'

'

'

196,000

'

'

'

'

'

'

'

'

'

196,000

Debt Instrument, Convertible, Remaining Discount Amortization Period

'

'

'

'

'4 years 255 days

'

'

'

'

'

'

'

'

'

'

Convertible Debt, Noncurrent

21,804,000

'

'

17,000,000

'

'

'

15,000,000

'

20,000,000

'

'

'

'

'

Notes Payable, Related Parties, Additional Borrowings Increase (Decrease)

'

'

'

'

'

'

'

'

'

'

5,000,000

'

'

'

'

Due to Related Parties

'

'

'

'

'

'

'

'

20,000,000

'

'

'

'

'

'

Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)

'

'

'

'

'

'

'

'

'

'

'

1,880,620

'

'

'

Fair Value Assumptions, Exercise Price (in Dollars per share)

'

'

'

'

'

'

'

'

'

'

'

'

$1.86

'

'

Deferred Costs, Noncurrent

'

'

'

'

'

'

'

'

'

1,200,000

'

'

'

'

'

Accrued Liabilities, Current

897,000

'

'

728,000

'

'

'

'

201,000

'

'

'

'

'

'

Long Term Debt Maximum Amount Lender Agreed To Provide Financial Assistance

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,000,000

'

Note_5_Convetible_Debt_Related3

Note 5. Convetible Debt - Related Party (Details) - Summary of Beneficial Conversion Feature Amounts Recorded (USD $)	0 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Nov. 26, 2013	Oct. 07, 2013	Dec. 31, 2013
Summary of Beneficial Conversion Feature Amounts Recorded [Abstract]	'	'	'
Borrowing Amount	$1,000	$1,000	$2,000
Convertible Shares	1,123,595	1,123,595	2,247,190
Share Price (in Dollars per share)	$1.01	$0.95	'
Gross Beneficial Conversion Feature	$135	$67	$202

Note_5_Convetible_Debt_Related4

Note 5. Convetible Debt - Related Party (Details) - Summary of our Convertible Debt-Related Party (USD $)	Dec. 31, 2013	Mar. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Sep. 19, 2012	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Dec. 31, 2013
In Thousands, unless otherwise specified			Replacement Note [Member]	Replacement Note [Member]	Replacement Note [Member]	The 2013 Note [Member]	The 2013 Note [Member]	The 2013 Note [Member]	Gross Amount [Member]	Convertible Debt [Member]	Net Amount [Member]
			Gross Amount [Member]	Net Amount [Member]		Gross Amount [Member]	Convertible Debt [Member]	Net Amount [Member]
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'	'	'	'
Gross Principal Amount Outstanding	$21,804	$17,000	$20,000	$20,000	$20,000	$2,000	'	$1,804	$22,000	'	$21,804
Unamortized Debt Discount	'	'	'	'	'	'	-196	'	'	-196	'
Net Amount Outstanding	$21,804	$17,000	$20,000	$20,000	$20,000	$2,000	'	$1,804	$22,000	'	$21,804

Note_5_Convetible_Debt_Related5

Note 5. Convetible Debt - Related Party (Details) - Debt Cost Expense and Interest Expense Related to Outstanding Borrowings (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Note 5. Convetible Debt - Related Party (Details) - Debt Cost Expense and Interest Expense Related to Outstanding Borrowings [Line Items]	'	'	'	'
Debt cost expense	'	'	'	$272
Interest expense	58	36	143	467
Related Party [Member]	'	'	'	'
Note 5. Convetible Debt - Related Party (Details) - Debt Cost Expense and Interest Expense Related to Outstanding Borrowings [Line Items]	'	'	'	'
Interest expense	$56	$32	$137	$454

Note_6_Common_Stock_Details

Note 6. Common Stock (Details) (USD $)	1 Months Ended		9 Months Ended		25 Months Ended
	Apr. 27, 2012	Apr. 30, 2012	Dec. 31, 2013	Dec. 31, 2012	Apr. 27, 2014	Jul. 26, 2012
Note 6. Common Stock (Details) [Line Items]	'	'	'	'	'	'
Maximum Amount Common Stock Available to Sell in Purchase Agreement	$15,000,000	'	'	'	$21,000,000	'
Common Stock, Other Value, Outstanding	'	'	'	'	75,000,000	'
Fair Value Assumptions, Expected Term	'	'	'	'	'3 years	'
Sale of Stock, Price Per Share (in Dollars per share)	'	'	'	'	'	$3
Proceeds from Sale of Treasury Stock	1,000,000	1,000,000	'	'	'	'
Stock Issued During Period, Shares, New Issues (in Shares)	'	'	'	'	175,333	'
Stock Issued During Period, Shares, Conversion of Convertible Securities (in Shares)	'	'	230,000	'	'	'
Debt Issuance Cost	'	'	122,000	'	'	'
Proceeds from Issuance of Common Stock	'	'	878,000	878,000	'	'
Commitment Shares [Member]	'	'	'	'	'	'
Note 6. Common Stock (Details) [Line Items]	'	'	'	'	'	'
Stock Issued During Period, Value, Conversion of Convertible Securities	'	'	1,000,000	'	'	'
Lincoln Park Capital Fund, LLC [Member]	'	'	'	'	'	'
Note 6. Common Stock (Details) [Line Items]	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues (in Shares)	'	'	'	'	175,333	'
Maximum [Member]	'	'	'	'	'	'
Note 6. Common Stock (Details) [Line Items]	'	'	'	'	'	'
Stock Issued During Period, Shares, New Issues (in Shares)	'	'	'	'	215,000	'
Stock Issued During Period, Value, Conversion of Convertible Securities	'	'	$15,000,000	'	'	'

Note_6_Common_Stock_Details_Su

Note 6. Common Stock (Details) - Summary Common Stock Issued and Cash Received (USD $)	1 Months Ended
In Thousands, except Share data, unless otherwise specified	Apr. 27, 2012	Apr. 30, 2012		Dec. 31, 2013	Mar. 31, 2013
Note 6. Common Stock (Details) - Summary Common Stock Issued and Cash Received [Line Items]	'	'		'	'
Number of Shares of Common Stock Issued	'	775,213		47,614,000	46,249,000
Share Price (in Dollars per share)	'	'		$0.01	$0.01
Gross Proceeds (in Dollars)	$1,000	$1,000		'	'
Initial Purchase Shares [Member]	'	'		'	'
Note 6. Common Stock (Details) - Summary Common Stock Issued and Cash Received [Line Items]	'	'		'	'
Number of Shares of Common Stock Issued	'	599,880		'	'
Share Price (in Dollars per share)	'	$1.67		'	'
Gross Proceeds (in Dollars)	'	1,000		'	'
Initial Commitment Shares [Member]	'	'		'	'
Note 6. Common Stock (Details) - Summary Common Stock Issued and Cash Received [Line Items]	'	'		'	'
Number of Shares of Common Stock Issued	'	160,000		'	'
Initial Additional Commitment Shares [Member]	'	'		'	'
Note 6. Common Stock (Details) - Summary Common Stock Issued and Cash Received [Line Items]	'	'		'	'
Number of Shares of Common Stock Issued	'	15,333	[1]	'	'
Share Price (in Dollars per share)	'	'	[1]	'	'
Gross Proceeds (in Dollars)	'	'	[1]	'	'
[1]	Calculated as follows: ($1.0 million stock purchase divided by $15.0 million total maximum amount) multiplied by 230,000 additional commitment shares.

Note_7_StockBased_Awards_Detai

Note 7. Stock-Based Awards (Details) (USD $)

0 Months Ended

3 Months Ended

9 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

Aug. 15, 2003

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Jul. 26, 2012

Aug. 15, 2007

Aug. 15, 2000

Dec. 31, 2013

Dec. 31, 2013

Mar. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Dec. 31, 2013

Annual Vesting [Member]

Restricted Stock [Member]

Restricted Stock [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

General and Administrative Expense [Member]

Cynthia F. Ansari [Member]

Katherine L. Wolf [Member]

Howard Zauberman [Member]

Howard Zauberman [Member]

Howard Zauberman [Member]

Cynthia F. Ansari [Member]

Note 7. Stock-Based Awards (Details) [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

450,000

'

'

'

'

7,000,000

5,000,000

4,500,000

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

10,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,200,000

1,200,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,125,000

612,458

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)

'

$0.56

$0.79

$0.65

$0.92

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value (in Dollars)

'

'

$37,000

'

$37,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value (in Dollars)

'

'

29,000

'

29,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value (in Dollars)

'

'

36,000

'

36,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value (in Dollars)

'

'

2,000

'

25,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number

'

'

'

'

'

'

'

'

'

207,902

122,044

'

'

'

'

'

'

'

'

'

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

'

'

'

'

'

'

'

'

300,000

120,392

'

'

'

'

'

'

'

'

'

'

Share-based Compensation (in Dollars)

'

171,000

[1]

197,000

499,000

[1]

1,209,000

'

'

'

'

'

'

289,000

150,000

[2]

185,000

[2]

415,000

[2]

1,092,000

[2]

'

'

'

'

Unrecognized Stock Based Compensation Expense Related To Options (in Dollars)

'

600,000

'

600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)

'

$1,300,000

'

$1,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

[1]

Reflects reversal of stock-based compensation expense of $289 thousand for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.

[2]

Reflects reversal of stock-based compensation expense of $289 thousand in the nine months ended December 31, 2013 for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.

Note_7_StockBased_Awards_Detai1

Note 7. Stock-Based Awards (Details) - Stock Options Activity (USD $)	0 Months Ended	1 Months Ended	9 Months Ended
	Aug. 15, 2003	Mar. 31, 2013	Dec. 31, 2013
Note 7. Stock-Based Awards (Details) - Stock Options Activity [Line Items]	'	'	'
Outstanding - Number of Shares (in Shares)	'	5,780,608	4,341,174
Oustanding - Exercise Price Range Minimum	'	$0.79	$0.85
Oustanding - Exercise Price Range Maximum	'	$4.88	$4.88
Outstanding - Weighted Average Exercise Price	'	$2.09	$1.80
Outstanding - Weighted Average Remaining Contractual Life	'	'6 years 219 days	'6 years 36 days
Exercisable at December 31, 2013	'	$0.79	$0.85
Exercisable at December 31, 2013	'	$4.88	$4.88
Vested and expected to vest at December 31, 2013	'	$0.79	$0.85
Vested and expected to vest at December 31, 2013	'	$4.88	$4.88
Granted (in Shares)	10,000	'	'
Granted	'	$0.79	$0.85
Granted	'	$4.88	$4.88
Granted [Member]	'	'	'
Note 7. Stock-Based Awards (Details) - Stock Options Activity [Line Items]	'	'	'
Oustanding - Exercise Price Range Minimum	'	'	$0.90
Oustanding - Exercise Price Range Maximum	'	'	$1.09
Exercisable at December 31, 2013	'	'	$0.90
Exercisable at December 31, 2013	'	'	$1.09
Vested and expected to vest at December 31, 2013	'	'	$0.90
Vested and expected to vest at December 31, 2013	'	'	$1.09
Granted (in Shares)	'	'	966,000
Granted	'	'	$0.90
Granted	'	'	$1.09
Granted	'	'	$1
Exercised [Member]	'	'	'
Note 7. Stock-Based Awards (Details) - Stock Options Activity [Line Items]	'	'	'
Exercised (in Shares)	'	'	0
Canceled [Member]	'	'	'
Note 7. Stock-Based Awards (Details) - Stock Options Activity [Line Items]	'	'	'
Canceled (1) (in Shares)	'	'	-2,405,434	[1]
Canceled (1)	'	'	$0.95	[1]
Canceled (1)	'	'	$3.62	[1]
Canceled (1)	'	'	$2.21	[1]
Exercisable [Member]	'	'	'
Note 7. Stock-Based Awards (Details) - Stock Options Activity [Line Items]	'	'	'
Oustanding - Exercise Price Range Minimum	'	'	$0.85
Oustanding - Exercise Price Range Maximum	'	'	$4.88
Exercisable at December 31, 2013 (in Shares)	'	'	3,430,403
Exercisable at December 31, 2013	'	'	$0.85
Exercisable at December 31, 2013	'	'	$4.88
Exercisable at December 31, 2013	'	'	$1.93
Exercisable at December 31, 2013	'	'	'5 years 109 days
Vested and expected to vest at December 31, 2013	'	'	$0.85
Vested and expected to vest at December 31, 2013	'	'	$4.88
Granted	'	'	$0.85
Granted	'	'	$4.88
Vested and Expected to Vest [Member]	'	'	'
Note 7. Stock-Based Awards (Details) - Stock Options Activity [Line Items]	'	'	'
Oustanding - Exercise Price Range Minimum	'	'	$0.85
Oustanding - Exercise Price Range Maximum	'	'	$4.88
Exercisable at December 31, 2013	'	'	$0.85
Exercisable at December 31, 2013	'	'	$4.88
Vested and expected to vest at December 31, 2013 (in Shares)	'	'	4,259,506
Vested and expected to vest at December 31, 2013	'	'	$0.85
Vested and expected to vest at December 31, 2013	'	'	$4.88
Vested and expected to vest at December 31, 2013	'	'	$1.81
Vested and expected to vest at December 31, 2013	'	'	'6 years
Granted	'	'	$0.85
Granted	'	'	$4.88
[1]	Includes cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari (1,125,000 stock options), and our former VP, Corporate Development and Chief Financial Officer, Katherine L. Wolf (612,458 stock options).

Note_7_StockBased_Awards_Detai2

Note 7. Stock-Based Awards (Details) - Restricted Stock Activity (Restricted Stock [Member], USD $)	9 Months Ended
	Dec. 31, 2013
Restricted Stock [Member]	'
Note 7. Stock-Based Awards (Details) - Restricted Stock Activity [Line Items]	'
Nonvested - Number of Shares	122,044
Nonvested - Weighted Average Grant Price (in Dollars per share)	$2.37
Granted	1,365,000
Granted (in Dollars per share)	$1
Vested	-120,392
Vested (in Dollars per share)	$1.74
Nonvested - Number of Shares	207,902
Nonvested - Weighted Average Grant Price (in Dollars per share)	$1.06

Note_7_StockBased_Awards_Detai3

Note 7. Stock-Based Awards (Details) - Black-Scholes Valuation Assumptions	3 Months Ended		9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Black-Scholes Valuation Assumptions [Abstract]	'	'	'	'
Risk-free interest rate	1.38%	0.91%	1.21%	1.02%
Expected life (in years)	'5 years 36 days	'6 years 109 days	'5 years 146 days	'6 years 146 days
Expected volatility	73.00%	81.00%	78.00%	84.00%

Note_7_StockBased_Awards_Detai4

Note 7. Stock-Based Awards (Details) - Stock-based Compensation Expense (USD $)	3 Months Ended				9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2013		Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'		'		'		'
Allocated stock-based compensation expense	$171	[1]	$197		$499	[1]	$1,209
Cost of Sales [Member]	'		'		'		'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'		'		'		'
Allocated stock-based compensation expense	15		6		57		75
General and Administrative Expense [Member]	'		'		'		'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'		'		'		'
Allocated stock-based compensation expense	150	[2]	185	[2]	415	[2]	1,092	[2]
Research and Development Expense [Member]	'		'		'		'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'		'		'		'
Allocated stock-based compensation expense	$6		$6		$27		$42
[1]	Reflects reversal of stock-based compensation expense of $289 thousand for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.
[2]	Reflects reversal of stock-based compensation expense of $289 thousand in the nine months ended December 31, 2013 for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.

Note_8_Treasury_Stock_Details_

Note 8. Treasury Stock (Details) - Summary Treasury Stock Activity (USD $)	3 Months Ended	9 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Summary Treasury Stock Activity [Abstract]	'	'	'
Number of Shares Repurchased	9,912	25,525	27,329
Cost (in Dollars)	$12	$28	$36
Weighted Average Purchase Price (in Dollars per share)	$1.26	$1.11	$1.32

Note_9_Segment_Information_Det

Note 9. Segment Information (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013
Note 9. Segment Information (Details) [Line Items]	'
Number of Reportable Segments	2
Cynthia F. Ansari [Member]	'
Note 9. Segment Information (Details) [Line Items]	'
Stock Granted, Value, Share-based Compensation, Forfeited (in Dollars)	289

Note_9_Segment_Information_Det1

Note 9. Segment Information (Details) - Key Financial Highlights By Reportable Segments (USD $)	3 Months Ended			9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013		Dec. 31, 2012	Dec. 31, 2013		Dec. 31, 2012	Mar. 31, 2013
Segment Reporting Information [Line Items]	'		'	'		'	'
Net sales	$4,507		$3,952	$12,127		$11,087	'
Gross profit	1,378		1,132	3,653		3,114	'
Operating (loss) income	-1,478		-1,526	-5,150		-6,452	'
Interest expense, net	-58		-35	-142		-463	'
Depreciation and amortization	170		197	532		603	'
Stock-based compensation expense	171	[1]	197	499	[1]	1,209	'
Total assets	11,485		10,909	11,485		10,909	11,377
Expenditures for fixed assets	7		38	53		93	'
Medical [Member]	'		'	'		'	'
Segment Reporting Information [Line Items]	'		'	'		'	'
Net sales	3,586		2,970	10,013		8,190	'
Gross profit	996		728	2,770		2,068	'
Operating (loss) income	-1,676		-1,750	-5,408		-6,783	'
Interest expense, net	-58		-35	-142		-463	'
Depreciation and amortization	168		192	523		585	'
Stock-based compensation expense	160	[1]	182	469	[1]	1,142	'
Total assets	11,736		10,885	11,736		10,885	'
Expenditures for fixed assets	7		38	53		93	'
Industrial [Member]	'		'	'		'	'
Segment Reporting Information [Line Items]	'		'	'		'	'
Net sales	921		982	2,114		2,897	'
Gross profit	382		404	883		1,046	'
Operating (loss) income	198		224	258		331	'
Depreciation and amortization	2		5	9		18	'
Stock-based compensation expense	11	[1]	15	30	[1]	67	'
Total assets	1,591		1,783	1,591		1,783	'
Adjustments [Member]	'		'	'		'	'
Segment Reporting Information [Line Items]	'		'	'		'	'
Stock-based compensation expense	'	[1]	'	'	[1]	'	'
Total assets	($1,842)		($1,759)	($1,842)		($1,759)	'
[1]	Reflects reversal of stock-based compensation expense of $289 thousand for the cancellation of unvested stock options granted to our former President and Chief Executive Officer, Cynthia F. Ansari.

Note_9_Segment_Information_Det2

Note 9. Segment Information (Details) - Reportable Segment Adjustments (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012
Reportable Segment Adjustments [Abstract]	'	'
Intercompany eliminations	($1,156)	($1,073)
Investment in subsidiaries	-686	-686
Total adjustments	($1,842)	($1,759)

Note_9_Segment_Information_Det3

Note 9. Segment Information (Details) - Reconciliation To Loss Before Provision For Income Taxes (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Dec. 31, 2012
Reconciliation To Loss Before Provision For Income Taxes [Abstract]	'	'	'	'
Operating loss	($1,478)	($1,526)	($5,150)	($6,452)
Interest expense, net	-58	-35	-142	-463
Other, net	-18	-6	-16	-47
Debt cost expense	'	'	'	-272
Loss on extinguishment of debt	'	'	'	-1,244
Loss before provision for income taxes	($1,554)	($1,567)	($5,308)	($8,478)